Show an ad over header. AMP

I am the FIRST!!!

Why picking a jury for the Derek Chauvin trial is so hard

The tough task of selecting a jury for former MPD officer Derek Chauvin's trial for the killing of George Floyd is set to begin Monday.

The state of play: "This case may be the most highly publicized criminal trial in a long time. ... That means that it's harder to find people who really have an open mind," Richard Frase, University of Minnesota Law School professor of criminal law, told Axios.


  • COVID-19 precautions, security measures and deeply-held feelings about race and policing "heighten" an already difficult process, added Roy Futterman, a clinical psychologist who specializes in jury selection.
  • Plus, there's the pressure that the outcome could spark more civil unrest in the Twin Cities and elsewhere. "That's a lot to place on their shoulders," Futterman added.

Another catch: Being unfamiliar with the facts of a case is usually seen as a plus. In this situation, it could be seen as disqualifying.

  • Those who claim to be in the dark "don't demonstrate the level of citizenship required for a case this serious," defense attorney A.L. Brown told The Star Tribune.

How it works: Attorneys will question prospective jurors to try to determine whether they can be fair-minded. Candidates already filled out a lengthy questionnaire probing everything from their media habits to views on police and Black Lives Matter.

  • Jurors can be dismissed "for cause," based on something they said or did that suggests an inability to render fair judgment. Each side has a limited number of "peremptory challenges," which can be used for pretty much any reason except race.

Between the lines: Juror questions can also preview both sides' eventual arguments.

  • Lawyers will often "ask questions just as much to raise an issue and prepare anyone who ends up on the jury for the issue that they want to have front of mind," Frase said.

What's next: Judge Peter Cahill has set aside three weeks — an unusually long window — to find 12 jurors and 4 alternates before opening statements begin March 29.

  • Of note: While the trial will be broadcast, jurors will remain off camera to protect their identities.

This story first appeared in the Axios Twin Cities newsletter, designed to help readers get smarter, faster on the most consequential news unfolding in their own backyard.

regular 4 post ff

infinite scroll 4 pff

GoodRx prices IPO at $33 per share, valued at $12.7 billion

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Keep reading...Show less

Fauci says transition delay harmful to public health as COVID-19 cases surge

NIAID Director Anthony Fauci said on CNN's "State of the Union" Sunday that President Trump's refusal to cooperate with President-elect Biden's transition team hurts public health as coronavirus cases surge across the country.

The state of play: As President Trump refuses to concede the election to President-elect Joe Biden, General Services Administration Administrator Emily Murphy has not signed documents declaring Biden the apparent winner, preventing the president-elect's agency review teams from having access to the information they need in order to get to work.

Keep reading...Show less

FDA authorizes Moderna's COVID-19 vaccine for emergency use

The Food and Drug Administration has issued an emergency use authorization (EUA) for Moderna's COVID-19 vaccine, one day after it was endorsed by a panel of independent experts.

Why it matters: The authorization of a second coronavirus vaccine, coming exactly one week after the FDA cleared Pfizer-BioNTech's vaccine for emergency use, marks another milestone on the country’s path to curbing the pandemic and increases access for millions of Americans.

Keep reading...Show less

EU regulator grants conditional approval to Pfizer-BioNTech vaccine

The European Medicines Agency (EMA) on Monday recommended approval for the Pfizer-BioNTech COVID-19 vaccine.

Why it matters: The milestone means the vaccine is just a step away from being distributed to millions of people in the European Union's 27 countries.

Keep reading...Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories
<!ENTITY lol2 “&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;“> <!ENTITY lol3 “&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;“> <!ENTITY lol4 “&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;“> ]> &lol4;